<DOC>
	<DOCNO>NCT01814826</DOCNO>
	<brief_summary>This study open-label , multicenter , phase 1b , dose-escalation study MLN4924 combination azacitidine adult patient AML . The patient population consist patient 60 year age old , previously diagnose World Health Organization ( WHO ) -defined AML , unlikely benefit standard induction therapy receive definitive treatment AML prior treatment azacitidine decitabine .</brief_summary>
	<brief_title>Study MLN4924 Plus Azacitidine Treatment-Naïve Patients With Acute Myelogenous Leukemia ( AML ) Who Are 60 Years Older</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Patients WHOdefined AML , 60 year age old , unlikely benefit standard induction therapy , define least 1 follow : 1 . Greater equal 75 year age 2 . Antecedent hematologic disease 3 . Known adverse cytogenetic risk 4 . Eastern Cooperative Oncology Group ( ECOG ) PS = 2 Patient must receive definitive treatment AML , define prior chemotherapy antileukemic activity ECOG PS 0 2 Expected survival longer 3 month enrollment study Female patient post menopausal , surgically sterile , agree practice 2 effective method contraception agree practice true abstinence Male patient agree practice effective barrier contraception agree practice true abstinence Voluntary write consent must give performance studyrelated procedure Suitable venous access studyrequired blood sample Adequate clinical laboratory value screen period specify protocol Able undergo bone marrow aspiration biopsy screen Previous treatment azacitidine decitabine Known favorable cytogenetic risk Any serious medical psychiatric illness Treatment investigational product Known hypersensitivity azacitidine mannitol Acute promyelocytic leukemia diagnose morphologic examination bone marrow , fluorescent situ hybridization cytogenetics peripheral blood bone marrow , accept analysis Active uncontrolled infection severe infectious disease Major surgery within 14 day first dose study drug Lifethreatening illness unrelated cancer Clinically uncontrolled central nervous system ( CNS ) involvement Known human immunodeficiency virus ( HIV ) positive Known hepatitis B surface antigenpositive , know suspect active hepatitis C infection Known hepatic cirrhosis severe preexist hepatic impairment Known cardiac/cardiopulmonary disease Left ventricular ejection fraction Known moderate severe chronic obstructive pulmonary disease , interstitial lung disease , pulmonary fibrosis Body mass index &gt; 40 kg/m² Treatment CYP3A inducer within 14 day first dose MLN4924 Systemic antineoplastic therapy radiotherapy within 14 day first dose study drug , except hydroxyurea Patients unwilling unable refrain use hydroxymethylglutaryl coenzyme A ( HMG CoA ) reductase inhibitor ( statin ) start 5 day initial study drug administration throughout study permit enroll</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>MLN4924</keyword>
	<keyword>Acute</keyword>
	<keyword>Myelogenous</keyword>
	<keyword>Leukemia</keyword>
</DOC>